Guggenheim initiated coverage of Foghorn Therapeutics (FHTX) with a Buy rating and $12 price target
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FHTX:
- Foghorn Therapeutics Reports Q3 2025 Financial Results
- Foghorn Therapeutics: Promising Pipeline and Strategic Collaborations Drive Buy Rating
- Foghorn Therapeutics CFO Kristian Humer Resigns
- Foghorn Therapeutics reports Q3 EPS (25c), consensus (30c)
- Foghorn Therapeutics: Promising Advancements in ARID1B-Degrader Program and Strategic Focus Justify Buy Rating